97 related articles for article (PubMed ID: 28400543)
1. [I. Identification of a Possible Therapeutic Target for Chondrosarcoma with IDH Mutant Inhibitors].
Nakagawa M; Nakatani F; Kitabayashi I
Gan To Kagaku Ryoho; 2017 Mar; 44(3):212-216. PubMed ID: 28400543
[No Abstract] [Full Text] [Related]
2. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
3. Metabolism: IDH2 drives cancer in vivo.
Lokody I
Nat Rev Cancer; 2013 Nov; 13(11):756-7. PubMed ID: 24132108
[No Abstract] [Full Text] [Related]
4. Anticancer drugs: IDH2 drives cancer in vivo.
Lokody I
Nat Rev Drug Discov; 2013 Nov; 12(11):826-7. PubMed ID: 24172328
[No Abstract] [Full Text] [Related]
5. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163019
[TBL] [Abstract][Full Text] [Related]
6. Induction of sarcomas by mutant IDH2.
Lu C; Venneti S; Akalin A; Fang F; Ward PS; Dematteo RG; Intlekofer AM; Chen C; Ye J; Hameed M; Nafa K; Agaram NP; Cross JR; Khanin R; Mason CE; Healey JH; Lowe SW; Schwartz GK; Melnick A; Thompson CB
Genes Dev; 2013 Sep; 27(18):1986-98. PubMed ID: 24065766
[TBL] [Abstract][Full Text] [Related]
7. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Azzi G; Velez M; Mathias-Machado MC
Curr Opin Oncol; 2014 Jul; 26(4):403-7. PubMed ID: 24867810
[TBL] [Abstract][Full Text] [Related]
12. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
Borger DR; Zhu AX
Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
[No Abstract] [Full Text] [Related]
13. Novel therapeutic approaches in chondrosarcoma.
Polychronidou G; Karavasilis V; Pollack SM; Huang PH; Lee A; Jones RL
Future Oncol; 2017 Mar; 13(7):637-648. PubMed ID: 28133974
[TBL] [Abstract][Full Text] [Related]
14. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
15. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
16. Enigmas of IDH mutations in hematology/oncology.
Heuser M; Araujo Cruz MM; Goparaju R; Chaturvedi A
Exp Hematol; 2015 Aug; 43(8):685-97. PubMed ID: 26032956
[TBL] [Abstract][Full Text] [Related]
17. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
18. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
Lam SW; van Langevelde K; Suurmeijer AJH; Cleven AHG; Bovée JVMG
Histopathology; 2019 Dec; 75(6):843-852. PubMed ID: 31297850
[TBL] [Abstract][Full Text] [Related]
19. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mutant IDH1 in acute myeloid leukaemia.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
[No Abstract] [Full Text] [Related]
[Next] [New Search]